이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study in Depression and Associated Painful Physical Symptoms

2012년 1월 10일 업데이트: Eli Lilly and Company

Duloxetine Versus Placebo in the Acute Treatment of Patients With Major Depressive Disorder and Associated Painful Physical Symptoms

The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than placebo when treating depression and its associated painful symptoms.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

527

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • California
      • Sherman Oaks, California, 미국, 91403
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Connecticut
      • Cromwell, Connecticut, 미국, 06416
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Florida
      • Fort Lauderdale, Florida, 미국, 33319
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Orlando, Florida, 미국, 32806
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Georgia
      • Atlanta, Georgia, 미국, 30308
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Illinois
      • Hoffman Estates, Illinois, 미국, 60194
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Springfield, Illinois, 미국, 62711
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Indiana
      • Evansville, Indiana, 미국, 47714
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Kentucky
      • Florence, Kentucky, 미국, 41042
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Louisiana
      • Lake Charles, Louisiana, 미국, 70601
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Massachusetts
      • Belmont, Massachusetts, 미국, 02478
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Boston, Massachusetts, 미국, 02135
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Michigan
      • Troy, Michigan, 미국, 48083
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New Jersey
      • Toms River, New Jersey, 미국, 08755
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Willingboro, New Jersey, 미국, 08046
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • New York
      • Brooklyn, New York, 미국, 11235
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Rochester, New York, 미국, 14618
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Staten Island, New York, 미국, 10305
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Ohio
      • Beachwood, Ohio, 미국, 44122
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Toledo, Ohio, 미국, 43623
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73109
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Oregon
      • Portland, Oregon, 미국, 97210
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Salem, Oregon, 미국, 97301
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18104
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Media, Pennsylvania, 미국, 19063
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Philadelphia, Pennsylvania, 미국, 19107
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Rhode Island
      • Lincoln, Rhode Island, 미국, 02865
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Tennessee
      • Memphis, Tennessee, 미국, 38119
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Texas
      • Wichita Falls, Texas, 미국, 76309
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Virginia
      • Richmond, Virginia, 미국, 23230
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Washington
      • Bellevue, Washington, 미국, 98007
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Wisconsin
      • Middleton, Wisconsin, 미국, 53562
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  • 푸에르토 리코
      • Caguas, 푸에르토 리코, 00725
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • San Juan, 푸에르토 리코, 00926
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria:

  • Meets criteria for Major Depressive Disorder (MDD) as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to 20 during the Screening Phase
  • At least 1 previous episode of depression
  • Painful physical symptoms with a score greater than or equal to 3 on the Brief Pain Inventory-Short Form (BPI-SF) average pain question
  • A Clinical Global Impression of Severity (CGI-S) score greater than or equal to 4 during the Screening Phase
  • Written informed consent

Key Exclusion Criteria:

  • Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device
  • Have previously completed or withdrawn from this study or any other study investigating duloxetine (unless no study drug was received)
  • Women of child-bearing potential who are not using a medically accepted means of contraception
  • Have any current (within past 6 months) DSM-IV-TR primary Axis I diagnosis other than MDD
  • Have a history of alcohol abuse and/or substance abuse or dependence within 1 year prior to being screened for the study
  • Have any prior history of bipolar disorder, psychosis, or schizophrenia
  • Have an Axis II disorder that would interfere with study compliance
  • Lack of response of any episode of major depression (lifetime of subject) to two or more adequate courses of antidepressant therapy, at a clinically appropriate dose for at least 4 weeks or, alternatively, in the judgment of the investigator, the subject meets criteria for treatment resistant depression
  • Have previously received treatment of MDD or Generalized Anxiety Disorder (GAD) with an adequate trial of duloxetine and did not respond or could not tolerate duloxetine
  • Diagnosis of acute liver injury or severe cirrhosis
  • Uncontrolled narrow-angle glaucoma
  • Positive urine drug screen for any substance of abuse
  • Have a serious medical illness, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require intervention, hospitalization, or use of an excluded medication during the study
  • History of a serious suicide attempt or subject judged clinically to be at serious suicidal risk
  • Requires continuous use of analgesics for 6 or more months because of chronic pain
  • Has pain of a known origin
  • Meets criteria for fibromyalgia as defined by the American College of Rheumatology
  • Experiences greater than or equal to 1 migraine headache per week
  • Have had electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS) within 1 year prior to being screened for the study
  • Initiating, changing, or stopping psychotherapy within 6 weeks prior to being screened for the study or at any time during the study
  • Investigator or subject anticipates initiating, changing, or stopping non-pharmacologic or alternative therapies for painful physical symptoms at any time during the study
  • Are taking any excluded medications within 7 days prior to randomization with the exception of fluoxetine which cannot be taken within 30 days prior to randomization
  • Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to randomization or have the potential need to use an MAOI during the study or within 5 days after discontinuation of study drug
  • Abnormal thyroid stimulating hormone
  • Has epilepsy or history of seizure disorder or received treatment with anticonvulsant medication for epilepsy or seizures

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약
의약품: Placebo
Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
실험적: 둘록세틴
의약품: Duloxetine
Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
다른 이름들:
  • 심발타
  • LY248686

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-Week Treatment Period
기간: Day 1 through 8 weeks
A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The overall change is based on the estimated main treatment effect. The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Day 1 through 8 weeks
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8
기간: Baseline, 8 weeks
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Baseline, 8 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
8주차에 Sheehan 장애 척도(SDS) 총계 및 항목 점수의 기준선으로부터의 변화
기간: 기준선, 8주
SDS는 참가자가 완료합니다. 참가자의 증상이 직장/사회/가정 생활에 미치는 영향을 평가하는 데 사용됩니다. 총 점수 범위는 0에서 30까지입니다. 값이 높을수록 참가자의 업무/사회/가정 생활에 더 큰 혼란이 있음을 나타냅니다. 각 항목 점수의 범위는 0에서 10까지이며 값이 높을수록 참여자의 직장/학교 생활(항목 1), 사회 생활/여가 활동(항목 2) 또는 가족 생활/가정 책임(항목 3)에 더 큰 지장이 있음을 나타냅니다. LS 평균 값은 치료, 조사자, 방문, 기준선, 치료*방문 상호작용 및 기준선*방문 상호작용에 대해 조정되었습니다.
기준선, 8주
8주차에 간단한 통증 인벤토리 심각도 및 간섭 점수(BPI-S/BPI-I)의 기준선에서 변경
기간: 기준선, 8주
통증 정도와 기능 장애를 측정합니다. 심각도 점수: 각 질문에 대해 0(통증 없음)에서 10(심한 통증). 간섭 점수: 일반적인 활동, 기분, 보행 능력, 정상적인 작업, 다른 사람과의 관계, 수면 및 삶의 즐거움에 대한 지난 24시간 동안의 통증 간섭을 평가하는 각 질문에 대해 0(방해하지 않음) ~ 10(완전히 방해함). 평균 간섭 = 개별 간섭 항목의 비결측 점수의 평균. 치료, 조사자, 방문, 기준선, 치료*방문 상호작용 및 기준선*방문 상호작용에 대해 조정된 LS 평균값.
기준선, 8주
Change From Baseline in the Percentage of Participants Achieving Remission up to Week 8
기간: Baseline, up to 8 weeks
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Remission is defined as achieving a MADRS total score ≤12.
Baseline, up to 8 weeks
Percentage of Participants Achieving Remission up to Week 8
기간: Up to 8 weeks
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale from 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Remission is defined as achieving a MADRS total score ≤12 at the last 2 nonmissing visits (for example, visit 3 [week 1] and visit 4 [week 2], or visit 4 [week 2] and visit 5 [week 4], or visit 5 [week 4] and visit 6 [week 8]).
Up to 8 weeks
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 4
기간: Baseline, 4 weeks
The MADRS is a rating scale for severity of depressive mood and symptoms. The MADRS has a 10-item checklist. Items are rated on a scale from 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Baseline, 4 weeks
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 2
기간: Baseline, 2 weeks
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, baseline, treatment*visit interaction, and baseline*visit interaction.
Baseline, 2 weeks
Patient Global Impression of Improvement (PGI-I) Score at Week 8
기간: 8 weeks
A scale that measures the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). The Least Squares (LS) Mean Value was adjusted for treatment, investigator, visit, and treatment*visit interaction.
8 weeks
Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on the Columbia Suicide Severity Rating Scale (C-SSRS) During the Double-Blind Treatment Phase
기간: Baseline through 8 weeks
The C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors, ideations, and acts are provided. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, and completed suicide. Suicidal ideation: a "yes" answer to any 1 of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. Suicidal acts: a "yes" answer to actual attempt or completed suicide.
Baseline through 8 weeks

기타 결과 측정

결과 측정
측정값 설명
기간
기준선에서 8주차까지의 맥박수 변화
기간: 기준선, 최대 8주차

8주차에 기준선에서 맥박수의 변화가 1차 분석입니다. 맥박의 1차 분석을 위해 최소 제곱(LS) 평균값을 치료, 조사자, 기준선, 치료*방문 상호작용 및 기준선*방문 상호작용에 대해 조정했습니다.

기준선에서 8주차까지의 맥박수 변화는 2차 분석입니다. LS 평균값은 치료, 조사자 및 기준선에 대해 조정되었습니다.
기준선, 최대 8주차
최대 8주까지 수축기 혈압(SBP) 및 확장기 혈압(DBP)의 기준선에서 변화
기간: 기준선, 최대 8주차

8주차에 SBP 및 DBP의 기준선으로부터의 변화가 1차 분석입니다. SBP 및 DBP의 1차 분석을 위해 치료, 조사자, 기준선, 치료*방문 상호작용 및 기준선*방문 상호작용에 대해 최소 제곱(LS) 평균값을 조정했습니다.

SBP 및 DBP의 기준선에서 8주까지의 변화는 2차 분석입니다. LS 평균값은 치료, 조사자 및 기준선에 대해 조정되었습니다.
기준선, 최대 8주차
체중 기준선에서 8주차까지의 변화
기간: 기준선, 최대 8주차

8주째 체중의 기준선으로부터의 변화가 1차 분석입니다. 체중의 1차 분석을 위해 치료, 조사자, 기준선, 치료*방문 상호작용 및 기준선*방문 상호작용에 대해 최소 제곱(LS) 평균값을 조정했습니다.

기준선에서 8주차까지의 체중 변화는 2차 분석입니다. LS 평균값은 치료, 조사자 및 기준선에 대해 조정되었습니다.
기준선, 최대 8주차
Number of Participants With Abnormal Laboratory Values During the Double-Blind Treatment Phase - High Creatinine
기간: Baseline through 8 weeks
Laboratory assessment of creatinine during the double-blind treatment phase. Normal creatinine ranges for males are 40.00 micromoles per liter (µmol/L) (low) to 110.00 µmol/L (high). Normal creatinine ranges for females are 31.00 µmol/L (low) to 101.00 µmol/L (high).
Baseline through 8 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Eli Lilly and Company

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2010년 3월 1일

기본 완료 (실제)

2011년 3월 1일

연구 완료 (실제)

2011년 3월 1일

연구 등록 날짜

최초 제출

2010년 2월 16일

QC 기준을 충족하는 최초 제출

2010년 2월 16일

처음 게시됨 (추정)

2010년 2월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2012년 2월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2012년 1월 10일

마지막으로 확인됨

2012년 1월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 13630
  • F1J-US-HMGU (기타 식별자: Eli Lilly and Company)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Duloxetine에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in South Korea

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

3
구독하다